Clinical infection characteristics and drug resistance trend of Acinetobacter baumannii in a hospital from 2020 to 2022
Objective To investigate the clinical distribution characteristics and drug resistance of Acinetobacter baumannii in a hospital,and to provide evidence for clinical medication and effective infection control.Methods The strains of isolated from clinical samples of a hospital from January 2020 to December 2022 were collected for routine identification and drug susceptibility test using Vitek Ⅱ automatic microbial analyzer.Results The 1 137 strains of Acinetobacter baumannii were mainly isolated from sputum,accounted for 84.61％.Male patients were more infected than female patients,and the proportion of patients ≥65 years old was the highest,accounted for 50.22％Acinetobacter baumannii strains were mainly distributed in the respiratory department and intensive care unit,accounted for 19.26％and 19.00％respectively.The resistance rate of Acinetobacter baumannii strains to most antibiotics tested was＞60％.The resistance rates to imipenem and meropenem were 63.07％-71.05％and 65.14％-73.17％,respectively.The resistance rate to tigacycline was the lowest,ranged from 3.67％to 6.10％.The drug resistance rates to ceftazidime(65.24％-76.14％),cefuroxime(94.21％-97.05％),ceftriaxone(92.07％-98.12％)and imipenem(70.12％-71.05％)all increased during 3 years,while the drug resistance rates to cefoperazone/sulbactam(71.04％-65.15％),cefepime(87.20％-66.22％),cefazolin(95.12％-91.15％),meropenem(73.17％-68.10％),levofloxacin(54.27％-42.09％)and amicacin(40.24％-23.06％)all decreased.The difference was statistically significant(P＜0.05).Conclusion The resistance of Acinetobacter baumannii was serious,the monitoring of bacterial resistance should be strengthened.Rational use of antibiotics should be adopted.
NETL
NSTL
万方数据
